IMUNON, Inc. announced on May 6, 2025, that data from its Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy will be published in the peer-reviewed journal Gynecologic Oncology. The full data review is scheduled for publication on June 3, 2025.
Concurrently, data from the OVATION 2 study will also be reviewed in an oral presentation during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2025. Dr. Premal H. Thaker, a key investigator, will be the lead author on the publication and presenter at ASCO.
This dual presentation in a prestigious journal and at a major oncology conference highlights the critical need for new ovarian cancer therapies and the strength of IMUNON’s TheraPlas platform technology. It provides significant scientific validation for IMNN-001's potential in treating newly diagnosed advanced epithelial ovarian cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.